XML 41 R30.htm IDEA: XBRL DOCUMENT v3.24.3
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Product Information [Line Items]        
Research and Development Expense $ 723,487 $ 27,936 $ 1,238,463 $ 67,095
Cash, FDIC Insured Amount 250,000   250,000  
Depreciation expenses 68,878 49,722 199,815 137,971
Grants costs     1,814,085 2,265,408
MDB Capital Holdings [Member]        
Product Information [Line Items]        
Loans payable 3,669,933   3,669,933  
Notes and Loans Payable 247,889   247,889  
Other Notes Payable 3,422,066   3,422,066  
Unsecured Debt $ 3,345,000   $ 3,345,000  
Debt Instrument, Interest Rate, Stated Percentage 5.00%   5.00%  
Repayments of Related Party Debt     $ 77,066  
Patents [Member]        
Product Information [Line Items]        
Legal fees     165,872 98,794
Grant [Member]        
Product Information [Line Items]        
Grant drawdowns $ 489,798 $ 704,162 1,807,706 2,265,408
Research and development costs     3,046,169 2,332,503
Grant [Member] | National Institud Of Health And Department Of Energy And Department Of Defense [Member]        
Product Information [Line Items]        
Grant drawdowns     $ 1,756,852 $ 2,180,581
Department Of Energy [Member]        
Product Information [Line Items]        
Government grants percentage     64.00%  
NIH [Member]        
Product Information [Line Items]        
Government grants percentage     36.00%  
Research and Development Expense [Member]        
Product Information [Line Items]        
Research and Development Expense     $ 19,186